Your browser doesn't support javascript.
loading
Modern science for better quality control of medicinal products "Towards global harmonization of 3Rs in biologicals": The report of an EPAA workshop.
Schutte, Katrin; Szczepanska, Anna; Halder, Marlies; Cussler, Klaus; Sauer, Ursula G; Stirling, Catrina; Uhlrich, Sylvie; Wilk-Zasadna, Iwona; John, David; Bopst, Martin; Garbe, Joerg; Glansbeek, Harrie L; Levis, Robin; Serreyn, Pieter-Jan; Smith, Dean; Stickings, Paul.
Afiliação
  • Schutte K; EU Commission, Directorate General for the Environment, Avenue Beaulieu 9, B-1160 Brussels, Belgium. Electronic address: katrin.schutte@ec.europa.eu.
  • Szczepanska A; European Federation of Pharmaceutical Industries and Associations (EFPIA), Rue du Trône 108, B-1050 Brussels, Belgium. Electronic address: anna.szczepanska@efpia.eu.
  • Halder M; EU Commission Joint Research Centre (JRC), Via E. Fermi, 2749, I-21027 Ispra, VA, Italy. Electronic address: marlies.halder@ec.europa.eu.
  • Cussler K; Paul-Ehrlich-Institut (PEI), Paul-Ehrlich-Straße 51-59, D-63225 Langen, Germany. Electronic address: klaus.cussler@pei.de.
  • Sauer UG; Scientific Consultancy - Animal Welfare, Hallstattfeld 16, D-85579 Neubiberg, Germany. Electronic address: ursula.sauer@sauerug.de.
  • Stirling C; Zoetis Ltd, Innovation House, Discover Park, Ramsgate Road, Sandwich, Kent CT12 9NJ, United Kingdom. Electronic address: catrina.stirling@zoetis.com.
  • Uhlrich S; Sanofi Pasteur, 1541 Avenue Marcel Merieux, 69280 Marcy l'Etoile, France. Electronic address: sylvie.uhlrich@sanofipasteur.com.
  • Wilk-Zasadna I; GSK Vaccines, Avenue Fleming, 1300 Wavre, Belgium. Electronic address: iwona.e.wilk-zasadna@gsk.com.
  • John D; IFAH-Europe, 168 Avenue de Tervueren, B-1150 Brussels, Belgium. Electronic address: djohn@ifahsec.org.
  • Bopst M; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland. Electronic address: martin.bopst@roche.com.
  • Garbe J; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland. Electronic address: joerg.garbe@roche.com.
  • Glansbeek HL; MSD Animal Health, Intervet Nederland B.V. Postbus 50, NL-5830 AB Boxmeer, The Netherlands. Electronic address: harrie.glansbeek@merck.com.
  • Levis R; Food and Drug Administration (FDA), 10903 New Hampshire Avenue, Silver Spring MD 20993, USA. Electronic address: robin.levis@fda.hhs.gov.
  • Serreyn PJ; Huvepharma, Uitbreidingstraat 80, B-2600 Berchem, Belgium. Electronic address: pieterjan.serreyn@huvepharma.com.
  • Smith D; Health Canada, A/L 0602B, Ottawa K1A 0K9, Ontario, Canada. Electronic address: dean.smith@hc-sc.gc.ca.
  • Stickings P; National Institute for Biological Standards and Control (NIBSC), Blanche Lane, South Mimms, Potters Bar Hertfordshire EN6 3QG, United Kingdom. Electronic address: paul.stickings@nibsc.org.
Biologicals ; 48: 55-65, 2017 Jul.
Article em En | MEDLINE | ID: mdl-28596049
ABSTRACT
This article summarizes the outcome of an international workshop organized by the European Partnership for Alternative Approaches to Animal Testing (EPAA) on Modern science for better quality control of medicinal products Towards global harmonization of 3Rs in biologicals. As regards the safety testing of biologicals, the workshop participants agreed to actively encourage the deletion of abnormal toxicity tests and target animal batch safety tests from all relevant legal requirements and guidance documents (country-specific guidelines, pharmacopoeia monographs, WHO recommendations). To facilitate the global regulatory acceptance of non-animal methods for the potency testing of, e.g., human diphtheria and tetanus vaccines and veterinary swine erysipelas vaccines, international convergence on the scientific principles of the use of appropriately validated in vitro assays for replacing in vivo methods was identified as an overarching goal. The establishment of scientific requirements for new assays was recognized as a further means to unify regulatory approaches in different jurisdictions. It was recommended to include key regulators and manufacturers early in the corresponding discussions. Manufacturers and responsible expert groups, e.g. at the European Directorate for the Quality of Medicines and Health Care of the Council of Europe or the European Medicines Agency, were invited to consider leadership for international collaboration.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Controle de Qualidade / Preparações Farmacêuticas / Indústria Farmacêutica Tipo de estudo: Prognostic_studies / Qualitative_research Limite: Animals / Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Controle de Qualidade / Preparações Farmacêuticas / Indústria Farmacêutica Tipo de estudo: Prognostic_studies / Qualitative_research Limite: Animals / Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article